Advanced Biotherapeutics Ltd., 20-22, Wenlock Road, London N1 7GU, UK.
Uppsala Inc., 67 Shady Brook Drive, Colora, MD 21917, USA.
Int J Mol Sci. 2024 Jun 4;25(11):6176. doi: 10.3390/ijms25116176.
This report describes major pathomechanisms of disease in which the dysregulation of host inflammatory processes is a major factor, with cardiovascular disease (CVD) as a primary model, and reviews strategies for countermeasures based on synergistic interaction between various agents, including drugs and generally regarded as safe (GRAS) natural medical material (NMM), such as , spice phytochemicals, and fruit seed flavonoids. The 15 well-defined CVD classes are explored with particular emphasis on the extent to which oxidative stressors and associated ischemia-reperfusion tissue injury contribute to major symptoms. The four major categories of pharmaceutical agents used for the prevention of and therapy for CVD: statins, beta blockers (β-blockers), blood thinners (anticoagulants), and aspirin, are presented along with their adverse effects. Analyses of major cellular and molecular features of drug- and NMM-mediated cardioprotective processes are provided in the context of their development for human clinical application. Future directions of the evolving research described here will be particularly focused on the characterization and manipulation of calcium- and calcineurin-mediated cascades of signaling from cell surface receptors on cardiovascular and immune cells to the nucleus, with the emergence of both protective and pathological epigenetic features that may be modulated by synergistically-acting combinations of drugs and phytochemicals in which phytochemicals interact with cells to promote signaling that reduces the effective dosage and thus (often) toxicity of drugs.
本报告描述了主要的疾病发病机制,其中宿主炎症过程的失调是一个主要因素,以心血管疾病 (CVD) 为主要模型,并回顾了基于各种药物和通常被认为安全 (GRAS) 的天然药物 (NMM) 之间协同相互作用的对策策略,如香料植物化学物质和水果种子类黄酮。探讨了 15 种明确界定的 CVD 类别的情况,特别强调了氧化应激因子和相关的缺血再灌注组织损伤对主要症状的影响程度。报告还介绍了用于预防和治疗 CVD 的四大类药物:他汀类药物、β 受体阻滞剂 (β-受体阻滞剂)、抗凝血剂和阿司匹林,以及它们的不良反应。根据其在人类临床应用中的发展情况,对药物和 NMM 介导的心脏保护过程的主要细胞和分子特征进行了分析。这里描述的不断发展的研究的未来方向将特别侧重于从心血管和免疫细胞表面受体到细胞核的钙和钙调神经磷酸酶介导的信号级联的特征描述和操纵,以及可能通过协同作用的药物和植物化学物质组合进行调节的保护性和病理性表观遗传特征,其中植物化学物质与细胞相互作用以促进信号转导,从而降低药物的有效剂量,因此(通常)降低药物的毒性。
Curr Vasc Pharmacol. 2017
Exerc Sport Sci Rev. 2013-7
Curr Pharm Des. 2022
Cardiovasc Hematol Disord Drug Targets. 2023
Ther Adv Endocrinol Metab. 2024-1-27
J Am Coll Cardiol. 2023-6-20
Nat Rev Cardiol. 2023-9